Coherus Biosciences Inc (CHRS)

$1.64

+0.07

(+4.46%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $1.52
    $1.68
    $1.64
    downward going graph

    7.62%

    Downside

    Day's Volatility :9.55%

    Upside

    2.09%

    downward going graph
  • $1.25
    $5.47
    $1.64
    downward going graph

    23.78%

    Downside

    52 Weeks Volatility :77.15%

    Upside

    70.02%

    downward going graph

Returns

PeriodCoherus Biosciences IncSector (Health Care)Index (Russel 2000)
3 Months
-24.15%
5.9%
0.0%
6 Months
-35.66%
5.5%
0.0%
1 Year
-64.16%
10.9%
0.0%
3 Years
-87.9%
15.6%
-17.0%

Highlights

Market Capitalization
199.6M
Book Value
- $0.72
Earnings Per Share (EPS)
-0.74
PEG Ratio
0.0
Wall Street Target Price
10.29
Profit Margin
-19.64%
Operating Margin TTM
-41.43%
Return On Assets TTM
-17.26%
Return On Equity TTM
-1657.06%
Revenue TTM
301.9M
Revenue Per Share TTM
2.94
Quarterly Revenue Growth YOY
137.6%
Gross Profit TTM
-58.4M
EBITDA
-156.6M
Diluted Eps TTM
-0.74
Quarterly Earnings Growth YOY
-0.75
EPS Estimate Current Year
-1.36
EPS Estimate Next Year
-0.23
EPS Estimate Current Quarter
-0.24
EPS Estimate Next Quarter
-0.22

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Coherus Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 527.44%

Current $1.64
Target $10.29

Company Financials

FY18Y/Y Change
Revenue
1.6M
↑ 0.0%
Net Income
-209.3M
↓ 12.11%
Net Profit Margin
-13.5K%
↑ 1852.9%
FY19Y/Y Change
Revenue
356.1M
↑ 22783.74%
Net Income
89.8M
↓ 142.91%
Net Profit Margin
25.23%
↑ 13478.89%
FY20Y/Y Change
Revenue
475.8M
↑ 33.63%
Net Income
132.2M
↑ 47.21%
Net Profit Margin
27.79%
↑ 2.56%
FY21Y/Y Change
Revenue
326.6M
↓ 31.37%
Net Income
-306.3M
↓ 331.63%
Net Profit Margin
-93.81%
↓ 121.6%
FY22Y/Y Change
Revenue
211.0M
↓ 35.37%
Net Income
-326.6M
↑ 6.63%
Net Profit Margin
-154.77%
↓ 60.96%
FY23Y/Y Change
Revenue
257.2M
↑ 21.89%
Net Income
-237.9M
↓ 27.17%
Net Profit Margin
-92.48%
↑ 62.29%
Q4 FY22Q/Q Change
Revenue
45.4M
↓ 0.16%
Net Income
-66.2M
↓ 28.65%
Net Profit Margin
-146.07%
↑ 58.34%
Q1 FY23Q/Q Change
Revenue
32.4M
↓ 28.48%
Net Income
-74.8M
↑ 12.88%
Net Profit Margin
-230.55%
↓ 84.48%
Q2 FY23Q/Q Change
Revenue
58.7M
↑ 81.02%
Net Income
-42.9M
↓ 42.67%
Net Profit Margin
-73.01%
↑ 157.54%
Q3 FY23Q/Q Change
Revenue
74.6M
↑ 27.0%
Net Income
-39.6M
↓ 7.53%
Net Profit Margin
-53.16%
↑ 19.85%
Q4 FY23Q/Q Change
Revenue
91.5M
↑ 22.74%
Net Income
-79.7M
↑ 100.94%
Net Profit Margin
-87.03%
↓ 33.87%
Q1 FY24Q/Q Change
Revenue
77.1M
↓ 15.8%
Net Income
102.9M
↓ 229.15%
Net Profit Margin
133.49%
↑ 220.52%
FY18Y/Y Change
Total Assets
99.5M
↓ 38.83%
Total Liabilities
138.1M
↑ 4.53%
FY19Y/Y Change
Total Assets
408.9M
↑ 311.12%
Total Liabilities
303.7M
↑ 119.99%
FY20Y/Y Change
Total Assets
841.6M
↑ 105.82%
Total Liabilities
560.7M
↑ 84.61%
FY21Y/Y Change
Total Assets
679.3M
↓ 19.29%
Total Liabilities
581.6M
↑ 3.73%
FY22Y/Y Change
Total Assets
480.8M
↓ 29.22%
Total Liabilities
618.3M
↑ 6.3%
FY23Y/Y Change
Total Assets
629.6M
↑ 30.94%
Total Liabilities
823.0M
↑ 33.12%
Q4 FY22Q/Q Change
Total Assets
480.8M
↓ 12.72%
Total Liabilities
618.3M
↓ 4.59%
Q1 FY23Q/Q Change
Total Assets
402.4M
↓ 16.31%
Total Liabilities
598.9M
↓ 3.13%
Q2 FY23Q/Q Change
Total Assets
469.6M
↑ 16.69%
Total Liabilities
644.4M
↑ 7.58%
Q3 FY23Q/Q Change
Total Assets
583.8M
↑ 24.32%
Total Liabilities
717.4M
↑ 11.33%
Q4 FY23Q/Q Change
Total Assets
629.6M
↑ 7.85%
Total Liabilities
823.0M
↑ 14.73%
Q1 FY24Q/Q Change
Total Assets
763.5M
↑ 21.27%
Total Liabilities
845.4M
↑ 2.72%
FY18Y/Y Change
Operating Cash Flow
-159.3M
↓ 20.48%
Investing Cash Flow
-1.2M
↓ 73.1%
Financing Cash Flow
105.4M
↓ 49.02%
FY19Y/Y Change
Operating Cash Flow
28.4M
↓ 117.8%
Investing Cash Flow
-12.7M
↑ 971.72%
Financing Cash Flow
89.4M
↓ 15.23%
FY20Y/Y Change
Operating Cash Flow
154.1M
↑ 443.63%
Investing Cash Flow
-14.4M
↑ 13.11%
Financing Cash Flow
223.9M
↑ 150.58%
FY21Y/Y Change
Operating Cash Flow
-37.4M
↓ 124.28%
Investing Cash Flow
-138.4M
↑ 861.11%
Financing Cash Flow
51.9M
↓ 76.83%
FY22Y/Y Change
Operating Cash Flow
-241.1M
↑ 544.17%
Investing Cash Flow
-166.9M
↑ 20.55%
Financing Cash Flow
54.3M
↑ 4.72%
Q4 FY22Q/Q Change
Operating Cash Flow
-100.0M
↑ 169.49%
Investing Cash Flow
-129.9M
↑ 28324.07%
Financing Cash Flow
6.6M
↓ 86.51%
Q1 FY23Q/Q Change
Operating Cash Flow
-68.7M
↓ 31.24%
Investing Cash Flow
17.5M
↓ 113.49%
Financing Cash Flow
3.8M
↓ 42.3%
Q2 FY23Q/Q Change
Operating Cash Flow
-38.9M
↓ 43.38%
Investing Cash Flow
41.4M
↑ 136.02%
Financing Cash Flow
54.3M
↑ 1328.1%

Technicals Summary

Sell

Neutral

Buy

Coherus Biosciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Coherus Biosciences Inc
Coherus Biosciences Inc
-3.09%
-35.66%
-64.16%
-87.9%
-91.12%
Moderna, Inc.
Moderna, Inc.
-9.73%
21.69%
-3.08%
-61.31%
759.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
2.19%
14.34%
48.43%
82.37%
258.01%
Novo Nordisk A/s
Novo Nordisk A/s
-7.8%
21.53%
62.25%
194.33%
441.74%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.55%
12.21%
36.13%
144.99%
180.32%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Coherus Biosciences Inc
Coherus Biosciences Inc
NA
NA
0.0
-1.36
-16.57
-0.17
NA
-0.72
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
32.06
32.06
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.58
48.58
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.67
31.67
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Coherus Biosciences Inc
Coherus Biosciences Inc
Buy
$199.6M
-91.12%
NA
-19.64%
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
759.82%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$119.6B
258.01%
32.06
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$631.0B
441.74%
48.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
180.32%
31.67
39.46%

Insights on Coherus Biosciences Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 91.52M → 77.06M (in $), with an average decrease of 15.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -79.65M → 102.87M (in $), with an average increase of 177.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 62.3% return, outperforming this stock by 126.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 194.3% return, outperforming this stock by 282.2%

Institutional Holdings

  • BlackRock Inc

    9.79%
  • Rubric Capital Management LP

    9.07%
  • Vanguard Group Inc

    8.79%
  • Temasek Holdings Ltd.

    6.43%
  • Kohlberg Kravis Roberts & Co LP

    2.65%
  • Morgan Stanley - Brokerage Accounts

    2.32%

Company Information

coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp

Organization
Coherus Biosciences Inc
Employees
249
CEO
Mr. Dennis M. Lanfear
Industry
Health Technology

FAQs